Journal of Neuro-Oncology

, Volume 104, Issue 2, pp 565–572 | Cite as

Meningeal carcinomatosis in breast cancer: prognostic factors and outcome

  • Carla Rameri Alexandre Silva de Azevedo
  • Marcelo Rocha Sousa Cruz
  • Ludmilla Thomé Domingos Chinen
  • Stela Verzinhasse Peres
  • Marcos Aurélio Peterlevitz
  • Artur Eugênio de Azevedo Pereira
  • Marcello Ferretti Fanelli
  • Daniel Luiz Gimenes
Clinical Study – Patient Study


Meningeal carcinomatosis (MC) occurs in up to 5% of breast cancer patients. Few studies have evaluated prognostic markers in breast cancer patients with MC. Our aim was to describe the treatment of breast cancer patients with MC, and identify prognostic factors related to survival. Sixty breast cancer patients that had a diagnosis of MC between January 2003 and December 2009 were included. The median age was 46 years (range 27–76). Most patients had invasive ductal carcinoma (78.3%) and high histological/nuclear grade (61.7/53.3%). Estrogen and progesterone receptors were positive in 51.7 and 43.3% of patients, respectively, and 15% were HER-2-positive. Symptoms at presentation were headache, cranial nerve dysfunction, seizures, and intracranial hypertension signals. Diagnosis was made by CSF cytology in 66.7% of cases and by MRI in 71.7%. Intrathecal (IT) chemotherapy was used in 68.3% of patients, and 21.6% received a new systemic treatment (chemo- or hormone therapy). Median survival was 3.3 months (range 0.03–90.4). There was no survival difference according to age, nuclear grade, hormonal and HER-2 status, CSF features, sites of metastasis, systemic and IT chemotherapy, or radiotherapy. However, histological grade and performance status had a significant impact on survival in the multivariate analysis. Only four papers have addressed prognostic factors in breast cancer patients with MC in the last two decades. The results of those reports are discussed here. High histological grade and poor performance status seem to impact survival of breast cancer patients with MC. Prospective studies are necessary to clarify the role of IT and systemic treatment in the treatment of those patients.


Leptomeninges Meningeal carcinomatosis Prognostic factor Central nervous system Breast cancer 


Conflict of interest



  1. 1.
    Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRefGoogle Scholar
  2. 2.
    Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329PubMedCrossRefGoogle Scholar
  3. 3.
    Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRefGoogle Scholar
  4. 4.
    Chamberlain MC (2005) Neoplasic meningitis. J Clin Oncol 23:3605–3613PubMedCrossRefGoogle Scholar
  5. 5.
    Chamberlain MC, Kormanik PRN (1997) Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35:55–64PubMedCrossRefGoogle Scholar
  6. 6.
    Rudnicka H, Niwińska A, Murawska M (2007) Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol 84:57–62PubMedCrossRefGoogle Scholar
  7. 7.
    Andre F, Slimane K, Bachelot T et al (2004) Breast cancer with synchronous metastasis: trends in survival during a 14-year period. J Clin Oncol 22:3302–3308PubMedCrossRefGoogle Scholar
  8. 8.
    Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920PubMedCrossRefGoogle Scholar
  9. 9.
    Boogerd W, Hart AAM, Sande JJV, Engelsman E (1991) Meningeal carcinomatosis in breast cancer. Cancer 15:1685–1695CrossRefGoogle Scholar
  10. 10.
    Bruna J, Gonzalez L, Miro J et al (2009) Leptomeningeal carcinomatosis. Prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381–389PubMedCrossRefGoogle Scholar
  11. 11.
    Waki F, Ando M, Takashima A et al (2009) Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 93:205–212PubMedCrossRefGoogle Scholar
  12. 12.
    Chamberlain MC, Johnston SK, Glantz MJ (2009) Neoplastic meningitis—related prognostic significance of the karnofsky performance status. Arch Neurol 66:74–78PubMedCrossRefGoogle Scholar
  13. 13.
    Chamberlain MC, Kormanik PA (1996) Prognostic significance of 111 indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46:1674–1677PubMedGoogle Scholar
  14. 14.
    Chamberlain MC, Johnston SK (2009) Neoplastic meningitis. Survival as a function of cerebrospinal fluid cytology. Cancer. doi: 10.1002/cncr.24210 Google Scholar
  15. 15.
    Sze G, Soletsky S, Bronen R, Krol G (1989) MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Roentgenol 153:1039–1049Google Scholar
  16. 16.
    Gomori JM, Heching N, Siegal Tali (1998) Leptomeningeal metastases: evaluation by gadolinium enhanced spinal magnetic resonance imaging. J Neurooncol 36:55–60PubMedCrossRefGoogle Scholar
  17. 17.
    Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMedCrossRefGoogle Scholar
  18. 18.
    Rakha EA, El-Sayed ME, Lee AHS et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158PubMedCrossRefGoogle Scholar
  19. 19.
    Rosen PP (1997) Rosen’s breast pathology. Lippincott-Raven, Philadelphia, pp 275–293Google Scholar
  20. 20.
    Jayson GC, Howell A, Harris M et al (1994) Carcinomatous meningitis in breast cancer: an aggressive disease variant. Cancer 74:3135–3141PubMedCrossRefGoogle Scholar
  21. 21.
    Gauthier H, Guilhaume MN, Bidard FC et al (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. doi: 10.1093/annonc/mdq232 Google Scholar
  22. 22.
    Fizazi K, Asselain B, Vincent-Salomon A et al (1996) Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77:1315–1323PubMedCrossRefGoogle Scholar
  23. 23.
    Slimane K, Andre F, Delaloge S et al (2004) Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15:1640–1644PubMedCrossRefGoogle Scholar
  24. 24.
    Hines SL, Vallow LA, Tan WW et al (2008) Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 19:1561–1565PubMedCrossRefGoogle Scholar
  25. 25.
    Dawood S, Broglio K, Esteva FJ et al (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187CrossRefGoogle Scholar
  26. 26.
    Rakha EA, El-Sayed M, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRefGoogle Scholar
  27. 27.
    Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40:2726–2733PubMedCrossRefGoogle Scholar
  28. 28.
    Gaviani P, Silvani A, Corsini E et al (2009) Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurol Sci 30:251–254PubMedCrossRefGoogle Scholar
  29. 29.
    Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumours. Clin Cancer Res 5:3394–3402PubMedGoogle Scholar
  30. 30.
    Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569PubMedGoogle Scholar
  31. 31.
    Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in Her2-overexpression metastatic breast cancer. Oncol Reports 15:1373–1377Google Scholar
  32. 32.
    Feyer P, Sautter-Bihl ML, Budach W et al (2010) DEGRO practical guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol 186:63–69PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Carla Rameri Alexandre Silva de Azevedo
    • 1
  • Marcelo Rocha Sousa Cruz
    • 1
  • Ludmilla Thomé Domingos Chinen
    • 1
  • Stela Verzinhasse Peres
    • 2
  • Marcos Aurélio Peterlevitz
    • 1
  • Artur Eugênio de Azevedo Pereira
    • 3
  • Marcello Ferretti Fanelli
    • 1
  • Daniel Luiz Gimenes
    • 1
  1. 1.Department of Medical OncologyHospital A. C. CamargoLiberdade, Sao PauloBrazil
  2. 2.Department of Epidemiology, Faculdade de Saúde PúblicaUniversidade de São PauloSao PauloBrazil
  3. 3.Instituto do Coração, Faculdade de Medicina Universidade de São PauloSao PauloBrazil

Personalised recommendations